FocalTherics (NASDAQ:FOCL) Stock Has Consensus Price Target of $7.75 According to Brokerages

FocalTherics (NASDAQ:FOCL) has been given a consensus recommendation of “Hold” by the five research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $7.75.

Several equities research analysts have commented on FOCL shares. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 target price on shares of FocalTherics in a research note on Friday, August 14th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of FocalTherics in a research report on Tuesday, August 25th. Mizuho set a $15.00 price target on shares of FocalTherics and gave the company an “outperform” rating in a report on Friday, July 17th. Wall Street Zen downgraded FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of FocalTherics in a report on Monday, August 17th.

FocalTherics Trading Down 2.6%

Shares of NASDAQ FOCL opened at $4.12 on Wednesday. The stock’s 50-day moving average is $4.25. The firm has a market cap of $154.62 million, a P/E ratio of -4.00 and a beta of -0.06. FocalTherics has a 12-month low of $1.75 and a 12-month high of $6.40.

FocalTherics (NASDAQ:FOCL) last released its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The firm had revenue of $13.20 million during the quarter. On average, research analysts predict that FocalTherics will post -0.82 earnings per share for the current year.

Insider Activity

In other FocalTherics news, CEO Ryan Rhodes acquired 21,000 shares of FocalTherics stock in a transaction dated Friday, August 14th. The stock was bought at an average cost of $4.75 per share, for a total transaction of $99,750.00. Following the purchase, the chief executive officer directly owned 626,649 shares in the company, valued at approximately $2,976,582.75. This represents a 3.47% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Joshua Levine purchased 10,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was bought at an average price of $4.75 per share, with a total value of $47,500.00. Following the completion of the purchase, the director owned 45,000 shares of the company’s stock, valued at approximately $213,750. This represents a 28.57% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 116,000 shares of company stock worth $551,000. 10.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in FocalTherics stock. Lido Advisors LLC acquired a new stake in FocalTherics (NASDAQ:FOCL) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,654 shares of the company’s stock, valued at approximately $40,000. 62.74% of the stock is currently owned by institutional investors and hedge funds.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.